Dynamk Capital overview
Stories about Dynamk Capital
Dynamk Capital wraps up maiden life science fund
Dynamk Capital has closed its inaugural life science fund at $65 million.
RoosterBio nets $15 mln
Frederick, Maryland-based RoosterBio Inc, a cell manufacturing platform, has raised in excess of $15 million in financing. Dynamk Capital led the round.
Dynamk Capital adds venture partner
Dynamk Capital, a venture firm focused on early-stage life sciences companies, has named Dr. Gustavo Mahler as a venture partner. Mahler is the former CEO of AGC Biologics.
Dynamk Capital adds venture partner
Dynamk Capital, a venture firm focused on early-stage life sciences companies, has named Dr. Gustavo Mahler as a venture partner. Mahler is the former CEO of AGC Biologics.
FloDesign Sonics grabs funding from Dynamk Capital
Wilbraham, Massachusetts-based FloDesign Sonics, a provider of acoustic separation technology, has secured an undisclosed amount of funding. The investor was Dynamk Capital.
Envisagenics picks up $2.25 mln seed
Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
Dynamk Capital collects capital for early-stage life sciences fund
Dynamk Capital has raised an undisclosed amount of capital in the first close of its early-stage venture fund focused on life sciences companies that provide tools, technologies and services. The fund is expected to close next year and will invest in eight to 10 companies.
Dynamk Capital contact information
Offices
250 West 34th Street, New York, 10119, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Ms. Daniella Kranjac | Job titleCo-Founding Partner | LocationNew York, United States | Email  ---------- |
| Mr. Mario M Kranjac | Job titleCo-Founding Partner | LocationNew York, United States | Email ----- |
| Mr. Sebastien Latapie | Job titlePrincipal | LocationNew York, United States | Email ----- |
Dynamk Capital funds managed
Closed funds: 1
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----- | Close dateApr 2021 | Strategy ---------- | |
Stories that mention Dynamk Capital
Vernal Biosciences picks up $21m
Vernal Biosciences, a technology-leading mRNA manufacturer and formulator of LNP-mRNA, has closed $21 million in financing.
Bionter AG procures $3m
Bionter AG, a Swiss provider of sub-visible particle testing, has raised $3 million in funding.
Envisagenics fetches Series A
Envisagenics, a developer of novel RNA splicing therapeutics, has secured an undisclosed amount of Series A funding.
Lightspeed Microscopy reels in $4m Series A
Lightspeed Microscopy Inc, a 3D pathology platform, has raised $4 million in Series A financing.
Curi Bio lands $6m Series A
Curi Bio Inc, a developer of human stem cell-based platforms for drug discovery, has raised $6 million in Series A financing.
Lucid Scientific gathers $3m
Atlanta-based Lucid Scientific, a biotechnology tools company, has raised $3 million in funding.
CellFE lands $4.8m
CellFE Inc, a developer of a microfluidics-based device to deliver gene-editing molecules, has raised $4.8 million in financing.
CellFE grabs $3.6 mln
CellFE Inc, a developer of a microfluidics-based device to deliver gene-editing molecules, has raised $3.6 million in funding.